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1061-95 Effect of Therapeutic Transcutaneous Ultrasound 
Following Thrombolysis: Results of the Perfusion by 
Thromobolytic and Ultrasound (PLUS) Trial
Michael P. Hudson, Adam B. Greenbaum, Laura Brenton, Miguel Fiol Sala, George R. 
McKendall, Jorge Bluguermann, E. Magnus Ohman, W. Douglas Weaver, Henry Ford 
Heart and Vascular Institute, Detroit, MI
Background: Therapeutic transcutaneous ultrasound (TUS) has been shown to
enhance thrombus dissolution and improve reperfusion success during thrombolysis
treatment.
Methods: In a double blind, randomized controlled, multicenter clinical trial, we random-
ized 396 patients to thrombolysis alone (control group) versus thrombolysis + TUS to
evaluate this adjunctive treatment in patients with acute ST-segment elevation myocardial
infarction (STEMI). We compared 60-minute TIMI grade flow, ST-segment resolution, and
other angiographic measures of perfusion plus clinical outcomes.
Results: Following interim analysis (n= 282), age (58 ± 10 vs. 55 ± 9 years), anterior inf-
arct location (33% vs. 33%), and symptom duration to thrombolysis (209 ± 164 vs. 198 ±
136 minutes) did not differ between control and TUS groups, respectively. Ultrasound
therapy was initiated 0.3 ± 3.6 minutes following thrombolysis with either rPA (37%) or
TNK-tPA (62%) and continued for 57 ± 8 minutes prior to protocol-mandated angiogra-
phy. Angiographic, ECG, and clinical outcomes are shown in Table.
Conclusions: Transcutaneous ultrasound, using pulsed energy, caused no mechanical
or device-related adverse events in STEMI patients receiving thrombolysis. Contrary to
our earlier animal and preclinical results using continuous wave energy, thrombolysis
plus pulsed wave TUS failed to improve TIMI flow grade, ST segment resolution, or myo-
cardial perfusion versus thrombolysis alone.
1061-96 Adrenomedullin Enhances Therapeutic Potency of Bone 
Marrow Transplantation for Acute Myocardial Infarction 
in Rats
Takafumi Fujii, Noritoshi Nagaya, Kazuhiro Nishigami, Hatsue Ishibashi-Ueda, Takashi 
Iwase, Takefumi Ito, Chikao Yutani, Shunji Sano, Hidezou Mori, National Cardiovascular 
Center Research Institute, Suita, Japan
Background: Adrenomedullin (AM) induces angiogenesis and inhibits endothelial cell
apoptosis through the PI3k/Akt pathway. Bone marrow transplantation has been shown
to induce angiogenesis in the ischemic heart. We investigated whether infusion of AM
enhances the therapeutic potency of bone marrow transplantation in rats with myocardial
infarction.
Methods: Immediately after coronary ligation, bone marrow-derived mononuclear cells
(MNCs) (5 ×106 cells) were injected into an ischemic area of myocardium in rats, followed
by subcutaneous infusion of 0.05µg/kg/min AM (AM-MNC group) or 0.9% saline (MNC-
group) for three days. Other rats received subcutaneous infusion of AM alone (AM group)
or saline (Control group) after coronary ligation.
Results: Hemodynamic and histological analyses were performed 4 weeks after treat-
ment. Left ventricular (LV) maximum dp/dt was significantly higher in the AM-MNC, MNC,
and AM groups than in the Control group (5076±201, 4083±262, and 4144±111 vs.
3338±97 mm Hg/s, P < 0.05). LV end-diastolic pressure was significantly lower in the
AM-MNC, MNC, and AM groups than in the Control group. Importantly, both parameters
were significantly improved in the AM-MNC group compared to those in the MNC and AM
groups. Infusion of AM significantly increased capillary density in ischemic myocardium,
suggesting angiogenic potency of AM. Interestingly, the capillary density was highest in
the AM-MNC group among the four groups. The number of TUNEL-positive cells in trans-
planted MNCs was smaller in the AM-MNC group than in the MNC group. In addition, the
number of lectin-positive cells (endothelial cells) in transplanted MNCs was larger in the
AM-MNC group than in the MNC group.
Conclusion: Infusion of AM enhanced the angiogenic potency of MNC transplantation,
resulting in marked improvement in cardiac function in rats with acute myocardial infarc-
tion. The beneficial effects of AM may be mediated by the anti-apoptotic effects and
angiogenic properties of AM itself.
1061-97 Efficacy of Granulocyte-Colony Stimulating Factor After 
Coronary Ligation in Rats: Evaluation by 
Echocardiographic Acoustic Quantification and 
Myocardial Contrast
Takashiro Hirano, Ryoko Azakami, Tomoko Kastuta, Kohei Okuda, Toshihiko Asanuma, 
Fuminobu Ishikura, Shintaro Beppu, Osaka University, Suita, Japan
Background and purpose:Granulocyte colony stimulating factor (G-CSF) reported to
improve the cardiac function after myocardial infarction (MI) by inducing bone marrow
cells (BMC), which differentiates into myocytes and vascular structures. The aim of this
study is to evaluate the effect of G-CSF after MI in the respect of myocardial perfusion,
remodeling and function.
Methods:The left coronary artery was ligated in 8 male rats after splenectomy. The
50µg/kg of G-CSF was injected under the skin once a day for 5 days before ligation and
given for 3 more days after ligation in 4 rats . Physiological saline was used as sham pro-
cedure in the other 4 rats. Ventricular area and its fractional area change (FAC) in the
short-axis were measured by the acoustic quantification method of SONOS 5500 (Phil-
ips) with high-frequency transducer. Non-perfused area was determined by intravenous
myocardial contrast echocardiography. Those data were measured before, just after, 2
and 4 weeks after coronary ligation.
Result:FAC decreased 2 weeks after ligation in both groups. During following 2 weeks,
however, it did not change in the G-CSF group (32.0±4.0 to 34.1±5.6% (ns)), while it
deteriorated significantly in the saline group (27.1±4.9 to 18.7±3.4%). Dilating ratio of
end diastolic area in the G-CSF group was smaller than that in the saline group at 4
weeks (4.2±0.9 vs. 6.6±0.3 p<0.01). The non-perfused area was significantly smaller in
the G-CSF group than the saline group 4 weeks after ligation (16.2±4.7 vs. 32.7±6.5%,
p<0.01), although it was almost identical between two groups just after ligation
(32.1±14.9 vs. 32.5±9.2%).
Conclusion:G-CSF should improve myocardial perfusion after coronary occlusion and
inhibit the left ventricular remodeling.
1061-98 Impaired Myocardial Perfusion Is a Major Explanation of 
the Poor Outcome Observed in Patients Undergoing 
Primary Angioplasty for ST-Segment Elevation 
Myocardial Infarction and Signs of Heart Failure
Giuseppe De Luca, Arnoud JW van't Hof, Harry Suryapranata, Jan Paul Ottervanger, AT 
Marcel Gosselink, Jan CA Hoorntje, Jan-Henk Dambrink, Felix Zijlstra, Menko-Jan de 
Boer, De Weezenlanden Hospital, Zwolle, The Netherlands
Background. The aim of the current study was to investigate the implication of myocar-
dial perfusion on outcome in patients with with ST-segment elevation myocardial infarc-
tion (STEMI) and signs of heart failure, treated with primary angioplasty.
Methods. Our population is represented by a cohort of 1548 consecutive patients with
STEMI underwent primary angioplasty. Congestive heart failure was defined as Killip
class > 1. All clinical, angiographic and follow-up data were prospectively collected. 
Results. Killip class was linearly associated with myocardial perfusion, and conse-
quently, with enzymatic infarct size, predischarge ejection fraction, and 1-year mortality
(see figure). Myocardial blush was independent predictor of 1-year mortality in patients
with advanced killip class at presentation.
Conclusions. Our study showed that patients with ventricular decompensation compli-
cating STEMI, have an impaired myocardial perfusion, that account for the poor outcome
observed in these patients. Thus, all the efforts should be aimed at improving myocardial
perfusion, beyond epicardial recanalization, in order to further improve the outcome of
these high-risk patients.
1061-99 Effects of L-Arginine in Myocardial Infarction: Double-
Blind, Placebo-Controlled Multicenter Pilot Study
Bronislaw Bednarz, Tomasz Chamiec, Leszek Ceremuzynski, and ARGAMI 
Investigators, Postgraduate Medical School, Warsaw, Poland
BACKGROUND. L-arginine, a substrate for nitric oxide has been shown to induce vasodi-
latation of the coronary vessels and thus is likely to improve perfusion of the ischemic
myocardium. The aim of the study was to assess the effect and safety of long-term treat-
ment with L-arginine on the clinical course of acute myocardial infarction with ST seg-
ment elevation ( STEMI ).
METHODS. 792 patients ( 551 men, mean age 64 years ) with STEMI up to 24h after the
onset of symptoms were randomized to oral L-arginine treatment ( 3.0 t.i.d for 30 days )
or placebo on the top of routine therapy. Main end points were: cardiovascular ( CV )
death, new non-fatal MI, stroke; secondary: in-hospital recurrent ischemia, serious
arrhythmias, heart failure calculated in all patients and in prespecified subgroups: diabe-
tes, hyperlipidemia, previous MI, hypertension.
RESULTS 
Thrombolysis
(n=141)
Thrombolysis +TUS
(n=141)
P value
TIMI Grade 3 Flow 50.4% 44.3% 0.34
> 50% ST-Segment Resolution 49.5% 48.8% 0.93
Corrected TIMI Frame Count < 40 46.7% 39.2% 0.27
TIMI Myocardial Perfusion “Blush” 
Grade 3
32.5% 38.3% 0.34
Death 3.8% 6.2% 0.32
Major Bleeding 3.8% 5.0% 0.61
